Citation Tools
PDFRegular and Young Investigator Award Abstracts
Clinical Trial Completed
629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma
Download to a citation manager
Download the citation for this article by clicking on one of the following citation managers:
- Cite this article as:
- 629 Neoadjuvant SEMA4D inhibitor pepinemab combination with nivolumab increases crosstalk between B cell and CD26hi T cell in patients with resectable stage III melanoma